1. Home
  2. BGX vs SCLX Comparison

BGX vs SCLX Comparison

Compare BGX & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

N/A

Current Price

$10.69

Market Cap

139.7M

Sector

Finance

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$9.43

Market Cap

59.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGX
SCLX
Founded
N/A
2011
Country
United States
United States
Employees
N/A
30
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
59.6M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
BGX
SCLX
Price
$10.69
$9.43
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
138.6K
30.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$749.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.38
$0.18
52 Week High
$12.65
$34.27

Technical Indicators

Market Signals
Indicator
BGX
SCLX
Relative Strength Index (RSI) 29.18 55.78
Support Level N/A $7.73
Resistance Level $11.89 $12.30
Average True Range (ATR) 0.13 0.64
MACD -0.02 0.23
Stochastic Oscillator 38.65 83.68

Price Performance

Historical Comparison
BGX
SCLX

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: